{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:44:53Z","timestamp":1789469093075,"version":"build-2803163510"},"reference-count":119,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Acquired Immunodeficiency Syndrome (AIDS), caused by the Human Immunodeficiency Virus (HIV), remains a major global public health issue. Current antiretroviral therapy (ART) does not fully eradicate HIV infection, and the virus can establish latent reservoirs in the body that are challenging to eliminate. Consequently, the development of new anti-HIV medications remains a critical necessity. Traditional drug development methods are time-consuming, financially demanding, and carry a high risk of failure. In contrast, computer-aided drug design (CADD) offers a promising alternative by leveraging computational techniques and bioinformatics data to accelerate drug development, reduce costs, and improve the success rates. This literature review provides a comprehensive overview of the CADD process, identifies key proteins involved in the HIV life cycle that serve as drug targets. It highlights successful examples where CADD has contributed to the development of inhibitors targeting these proteins. Additionally, the review discusses emerging strategies and limitations of CADD in anti-HIV drug research, offering insights into its potential to revolutionize future therapeutic efforts.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1873962","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:34:21Z","timestamp":1789464861000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cutting-edge developments in computer-aided anti-HIV drug design"],"prefix":"10.3389","volume":"17","author":[{"given":"Weiying","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine, First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenda","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.tips.2021.10.004","article-title":"Update and latest advances in antiretroviral therapy","volume":"43","author":"Men\u00e9ndez-Arias","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/med.21544","article-title":"Challenges and approaches in the discovery of human immunodeficiency virus type-1 non-nucleoside reverse transcriptase inhibitors","volume":"39","author":"Battini","year":"2019","journal-title":"Med Res Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fviro.2025.1705632","article-title":"A next-generation strategy for HIV-1 vaccination: computational design of a multi-epitope subunit vaccine targeting global circulating variants","volume":"5","author":"Khan","year":"2026","journal-title":"Front Virol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/0956462418758115","article-title":"Modes of HIV transmission among adolescents and young adults aged 10-24 years in Kenya","volume":"29","author":"Ng'eno","year":"2018","journal-title":"Int J STD AIDS"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2017.05.001","article-title":"The global HIV epidemic: What the pathologist needs to know","volume":"34","author":"Del Rio","year":"2017","journal-title":"Semin Diagn Pathol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12879-018-3126-5","article-title":"Mother-to-child transmission of HIV infection and its associated factors in Ethiopia: a systematic review and meta-analysis","volume":"18","author":"Kassa","year":"2018","journal-title":"BMC Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260941","article-title":"Mother-to-child transmission of HIV infection and its associated factors in the district of Bilene, Gaza Province-Mozambique","volume":"16","author":"Os\u00f3rio","year":"2021","journal-title":"PloS One"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/326435a0","article-title":"The chronology of AIDS research","volume":"326","author":"Gallo","year":"1987","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/science.6189183","article-title":"Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)","volume":"220","author":"Barr\u00e9-Sinoussi","year":"1983","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/v12040471","article-title":"Role of divalent cations in HIV-1 replication and pathogenicity","volume":"12","author":"Khan","year":"2020","journal-title":"Viruses"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1684\/vir.2019.0789","article-title":"Physiopathology of HIV-2 infection","volume":"23","author":"Visseaux","year":"2019","journal-title":"Virologie (Montrouge)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/v14010152","article-title":"HIV-1 and HTLV-1 transmission modes: mechanisms and importance for virus spread","volume":"14","author":"Kalinichenko","year":"2022","journal-title":"Viruses"},{"key":"B13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41579-025-01202-w","article-title":"Phylogenetics and molecular evolution to understand and curb the HIV pandemic","volume":"24","author":"G\u00fcnthard","year":"2026","journal-title":"Nat Rev Microbiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/v13050839","article-title":"HIV protease: historical perspective and current research","volume":"13","author":"Weber","year":"2021","journal-title":"Viruses"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2016.08.010","article-title":"Hiv-2 molecular epidemiology","volume":"46","author":"Visseaux","year":"2016","journal-title":"Infect Genet Evol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13280","article-title":"Delayed disease progression in HIV-2: the importance of TRIM5\u03b1 and the retroviral capsid","volume":"196","author":"Boswell","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ph15111415","article-title":"Implications of fragment-based drug discovery in tuberculosis and HIV","volume":"15","author":"Mallakuntla","year":"2022","journal-title":"Pharm (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262210909","article-title":"The origins and genetic diversity of HIV-1: evolutionary insights and global health perspectives","volume":"26","author":"Alexiev","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2025.2492208","article-title":"Grand challenges on HIV\/AIDS in China - the 5th symposium, Yunnan 2024","volume":"14","author":"Chen","year":"2025","journal-title":"Emerg Microbes Infect"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2025.128229","article-title":"Targeting HIV-1 immune escape mechanisms: Key advances and challenges in HIV-1 vaccine design","volume":"299","author":"Fang","year":"2025","journal-title":"Microbiol Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/science.add6502","article-title":"Vaccination induces HIV broadly neutralizing antibody precursors in humans","volume":"378","author":"Leggat","year":"2022","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057755","article-title":"Risk in vaccine research and development quantified","volume":"8","author":"Pronker","year":"2013","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: New estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J Health Econ"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2174\/0929867328666210708090123","article-title":"Recent advances in computer-aided antiviral drug design targeting HIV-1 integrase and reverse transcriptase associated ribonuclease H","volume":"29","author":"Yang","year":"2022","journal-title":"Curr Med Chem"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2174\/0929867328666210114124744","article-title":"Recent advances in small-molecule HIV-1 integrase inhibitors","volume":"28","author":"Zhang","year":"2021","journal-title":"Curr Med Chem"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1570162x18666200824104140","article-title":"Emerging trends in the long-acting antiretroviral therapy: current status and therapeutic challenges","volume":"19","author":"Labh","year":"2021","journal-title":"Curr HIV Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1038\/s41467-021-22628-9","article-title":"High-resolution view of HIV-1 reverse transcriptase initiation complexes and inhibition by NNRTI drugs","volume":"12","author":"Ha","year":"2021","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/biom13010088","article-title":"Efavirenz: history, development and future","volume":"13","author":"Costa","year":"2022","journal-title":"Biomolecules"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.811357","article-title":"Effectiveness and safety analysis of PIs\/r based dual therapy in treatment-na\u00efve, HIV\/AIDS patients: A network meta analysis of randomized controlled trials","volume":"13","author":"Hui","year":"2022","journal-title":"Front Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01379-9","article-title":"HIV-1 integrase inhibitors: A comparative review of efficacy and safety","volume":"80","author":"Scarsi","year":"2020","journal-title":"Drugs"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106343","article-title":"HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance","volume":"57","author":"Mbhele","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.01063","article-title":"Protein- and peptide-based virus inactivators: inactivating viruses before their entry into cells","volume":"11","author":"Su","year":"2020","journal-title":"Front Microbiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/v13050735","article-title":"HIV-1 entry and membrane fusion inhibitors","volume":"13","author":"Xiao","year":"2021","journal-title":"Viruses"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01386-w","article-title":"Fostemsavir: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14020138","article-title":"Infectious RNA: human immunodeficiency virus (HIV) biology, therapeutic intervention, and the quest for a vaccine","volume":"14","author":"van Heuvel","year":"2022","journal-title":"Toxins (Basel)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.31083\/fbl37412","article-title":"HIV-1 entry mechanisms: protein-host receptor interactions and membrane fusion dynamics","volume":"30","author":"Elalouf","year":"2025","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/cells12101351","article-title":"HIV-host cell interactions","volume":"12","author":"Masenga","year":"2023","journal-title":"Cells"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713104","article-title":"HIV infection: shaping the complex, dynamic, and interconnected network of the cytoskeleton","volume":"24","author":"Cabrera-Rodr\u00edguez","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/v12091005","article-title":"Going beyond integration: the emerging role of HIV-1 integrase in virion morphogenesis","volume":"12","author":"Elliott","year":"2020","journal-title":"Viruses"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.05095-11","article-title":"Timing of the components of the HIV life cycle in productively infected CD4+ T cells in a population of HIV-infected individuals","volume":"85","author":"Murray","year":"2011","journal-title":"J Virol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/v14030478","article-title":"Advances in HIV-1 assembly","volume":"14","author":"Lerner","year":"2022","journal-title":"Viruses"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073659","article-title":"A review of FDA-approved anti-HIV-1 drugs, anti-gag compounds, and potential strategies for HIV-1 eradication","volume":"25","author":"Sever","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B45","unstructured":""},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9040255","article-title":"Modeling of the HIV-1 life cycle in productively infected cells to predict novel therapeutic targets","volume":"9","author":"Shcherbatova","year":"2020","journal-title":"Pathogens"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/v12090940","article-title":"HIV-1 maturation: lessons learned from inhibitors","volume":"12","author":"Kleinpeter","year":"2020","journal-title":"Viruses"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2021.01.076","article-title":"Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs","volume":"172","author":"Tompa","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add7434","article-title":"Critical mechanistic features of HIV-1 viral capsid assembly","volume":"9","author":"Gupta","year":"2023","journal-title":"Sci Adv"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17460441.2025.2468289","article-title":"High performance-oriented computer aided drug design approaches in the exascale era","volume":"20","author":"Rizzi","year":"2025","journal-title":"Expert Opin Drug Discov"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1039\/d5cp00380f","article-title":"Molecular dynamics-driven drug discovery","volume":"27","author":"Yan","year":"2025","journal-title":"Phys Chem Chem Phys"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2174\/0115734064384472250716144736","article-title":"Recent advances in molecular docking techniques: Transforming perspectives in distinct drug targeting and drug discovery approaches","volume":"22","author":"Ansari","year":"2025","journal-title":"Med Chem"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23040767","article-title":"Computational simulation studies on the binding selectivity of 1-(1H-benzimidazol-5-yl)-5-aminopyrazoles in complexes with FGFR1 and FGFR4","volume":"23","author":"Pan","year":"2018","journal-title":"Molecules"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-024-10979-6","article-title":"Ligand and structure-based virtual screening approaches in drug discovery: Minireview","volume":"29","author":"da Rocha","year":"2025","journal-title":"Mol Divers"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/molecules201219880","article-title":"Pharmacophore models and pharmacophore-based virtual screening: Concepts and applications exemplified on hydroxysteroid dehydrogenases","volume":"20","author":"Kaserer","year":"2015","journal-title":"Molecules"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2017.1336157","article-title":"The advancement of multidimensional QSAR for novel drug discovery - Where are we headed","volume":"12","author":"Wang","year":"2017","journal-title":"Expert Opin Drug Discov"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2020.1798926","article-title":"Open access in silico tools to predict the ADMET profiling of drug candidates","volume":"15","author":"Kar","year":"2020","journal-title":"Expert Opin Drug Discov"},{"key":"B58","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/bs.enz.2025.06.005","article-title":"Computational approaches for designing viral protease inhibitors","volume":"58","author":"Bonardi","year":"2025","journal-title":"Enzymes"},{"key":"B59","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/978-1-61779-520-6_13","article-title":"Application of SBDD to the discovery of new antibacterial drugs","volume":"841","author":"Finn","year":"2012","journal-title":"Methods Mol Biol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241813953","article-title":"An updated review on developing small molecule kinase inhibitors using computer-aided drug design approaches","volume":"24","author":"Li","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiolchem.2025.108430","article-title":"A critical address to advancements and challenges in computational strategies for structural prediction of protein in recent past","volume":"117","author":"Fatima Ali","year":"2025","journal-title":"Comput Biol Chem"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv951","article-title":"PubChem substance and compound databases","volume":"44","author":"Kim","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1021\/ci100275a","article-title":"Assessing the performance of the MM\/PBSA and MM\/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations","volume":"51","author":"Hou","year":"2011","journal-title":"J Chem Inf Model"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.5c00921","article-title":"AI-designed molecules in drug discovery, structural novelty evaluation, and implications","volume":"65","author":"Xie","year":"2025","journal-title":"J Chem Inf Model"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.5c00029","article-title":"Scaffold hopping with generative reinforcement learning","volume":"65","author":"Rossen","year":"2025","journal-title":"J Chem Inf Model"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.4c01107","article-title":"Diffusion models in de novo drug design","volume":"64","author":"Alakhdar","year":"2024","journal-title":"J Chem Inf Model"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30010018","article-title":"Generation of rational drug-like molecular structures through a multiple-objective reinforcement learning framework","volume":"30","author":"Zhang","year":"2024","journal-title":"Molecules"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.27514","article-title":"Pre-training strategy for antiviral drug screening with low-data graph neural network: A case study in HIV-1 K103N reverse transcriptase","volume":"46","author":"Boonpalit","year":"2025","journal-title":"J Comput Chem"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2025.169100","article-title":"Kinetic investigation of resistance to Islatravir conferred by mutations in HIV-1 reverse transcriptase","volume":"437","author":"Zalenski","year":"2025","journal-title":"J Mol Biol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.0c00967","article-title":"Avoiding drug resistance in HIV reverse transcriptase","volume":"121","author":"Cilento","year":"2021","journal-title":"Chem Rev"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2019.11.011","article-title":"Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance","volume":"61","author":"Xavier Ruiz","year":"2020","journal-title":"Curr Opin Struct Biol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.1998.2208","article-title":"Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution","volume":"284","author":"Ding","year":"1998","journal-title":"J Mol Biol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jmb.2008.10.071","article-title":"Structure and function of HIV-1 reverse transcriptase: Molecular mechanisms of polymerization and inhibition","volume":"385","author":"Sarafianos","year":"2009","journal-title":"J Mol Biol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/med.22080","article-title":"Deciphering the enigmas of non-nucleoside reverse transcriptase inhibitors (NNRTIs): A medicinal chemistry expedition towards combating HIV drug resistance","volume":"45","author":"Zhang","year":"2025","journal-title":"Med Res Rev"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/1751-7915.70317","article-title":"Recent developments in HIV antivirals: The prospect of prophylactic drugs to change the pandemic","volume":"19","author":"Br\u00fcssow","year":"2026","journal-title":"Microb Biotechnol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3947\/ic.2025.0070","article-title":"Long-term effectiveness and tolerability of dolutegravir\/lamivudine in Korea: A 3-year follow up study","volume":"58","author":"Seong","year":"2026","journal-title":"Infect Chemother"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-026-03544-0","article-title":"Safety and effectiveness analysis of dolutegravir and dolutegravir\/abacavir\/lamivudine in Japanese people living with HIV: 10 years of post-marketing surveillance","author":"Sebata","year":"2026","journal-title":"Adv Ther"},{"key":"B78","article-title":"Nevirapine","volume-title":"Statpearls","author":"Rehman","year":"2024"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2022.2081153","article-title":"Cabotegravir\/rilpivirine: The last FDA-approved drug to treat HIV","volume":"20","author":"Taki","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2019.11.010","article-title":"Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): Our past twenty years","volume":"10","author":"Zhuang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1097\/qai.0000000000003787","article-title":"Doravirine resistance patterns identified through week 192 in the DRIVE-FORWARD and DRIVE-AHEAD phase 3 clinical trials","volume":"101","author":"Orkin","year":"2026","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B82","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/2040206615612208","article-title":"Design, synthesis, and anti-HIV-1 activity of 1-substituted 3-(3,5-dimethylbenzyl)triazine derivatives","volume":"24","author":"Sakakibara","year":"2015","journal-title":"Antivir Chem Chemother"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2009.07.031","article-title":"Substituted tetrahydroquinolines as potent allosteric inhibitors of reverse transcriptase and its key mutants","volume":"19","author":"Su","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2011.05.024","article-title":"Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors","volume":"19","author":"Zhang","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"B85","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.bioorg.2016.05.009","article-title":"Rational design, synthesis, anti-HIV-1 RT and antimicrobial activity of novel 3-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-1-(piperazin-1-yl)propan-1-one derivatives","volume":"67","author":"Chander","year":"2016","journal-title":"Bioorg Chem"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1093\/chemse\/bjad035","article-title":"Anti-HIV drugs lopinavir\/ritonavir activate bitter taste receptors","volume":"48","author":"Chen","year":"2023","journal-title":"Chem Senses"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116900","article-title":"A mini-review on integrase inhibitors: The cornerstone of next-generation HIV treatment","volume":"279","author":"Shalbi","year":"2024","journal-title":"Eur J Med Chem"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkag080","article-title":"Baseline resistance mutations and virological response to dolutegravir in treatment-na\u00efve patients: A multicentre NGS study","volume":"81","author":"Inciarte","year":"2026","journal-title":"J Antimicrob Chemother"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101991","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: Five-year follow-up from two randomized trials","volume":"59","author":"Sax","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01471-15","article-title":"Interaction between reverse transcriptase and integrase is required for reverse transcription during HIV-1 replication","volume":"89","author":"Tekeste","year":"2015","journal-title":"J Virol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.24.7333","article-title":"Structure of a two-domain fragment of HIV-1 integrase: Implications for domain organization in the intact protein","volume":"20","author":"Wang","year":"2001","journal-title":"EMBO J"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M117.816793","article-title":"Structure-function analyses unravel distinct effects of allosteric inhibitors of HIV-1 integrase on viral maturation and integration","volume":"293","author":"Bonnard","year":"2018","journal-title":"J Biol Chem"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20081943","article-title":"Non-cryogenic structure and dynamics of HIV-1 integrase catalytic core domain by X-ray free-electron lasers","volume":"20","author":"Park","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.4c00309","article-title":"AlphaFold meets de novo drug design: Leveraging structural protein information in multitarget molecular generative models","volume":"64","author":"Bernatavicius","year":"2024","journal-title":"J Chem Inf Model"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01681","article-title":"Discovery and optimization of novel pyrazolopyrimidines as potent and orally bioavailable allosteric HIV-1 integrase inhibitors","volume":"63","author":"Li","year":"2020","journal-title":"J Med Chem"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115541","article-title":"Design, synthesis and SAR study of bridged tricyclic pyrimidinone carboxamides as HIV-1 integrase inhibitors","volume":"28","author":"Patel","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2013.09.009","article-title":"Synthesis, docking, and biological studies of phenanthrene \u03b2-diketo acids as novel HIV-1 integrase inhibitors","volume":"23","author":"Sharma","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"B102","doi-asserted-by":"publisher","first-page":"290","DOI":"10.2174\/011570162x261377231107110447","article-title":"Design, synthesis, docking studies, and biological evaluation of novel 2-hydroxyacetophenone derivatives as anti-HIV-1 agents","volume":"21","author":"Oliaie","year":"2023","journal-title":"Curr HIV Res"},{"key":"B103","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1038\/s41598-022-07012-x","article-title":"Prediction and molecular field view of drug resistance in HIV-1 protease mutants","volume":"12","author":"Wang","year":"2022","journal-title":"Sci Rep"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/bs.enz.2025.06.001","article-title":"HIV protease and its inhibition","volume":"58","author":"Rusconi","year":"2025","journal-title":"Enzymes"},{"key":"B105","article-title":"Ritonavir","volume-title":"Statpearls","author":"Talha","year":"2024"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3390\/v17060850","article-title":"Integrative computational approaches for understanding drug resistance in HIV-1 protease subtype C","volume":"17","author":"Venkatachalam","year":"2025","journal-title":"Viruses"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.22.8805","article-title":"X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor","volume":"87","author":"Swain","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"B108","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/978-1-0716-4196-5_11","article-title":"Structural and functional studies on HIV protease: mechanism of action, subtypes, inhibitors, and drug resistance","volume":"2867","author":"Venkatachalam","year":"2025","journal-title":"Methods Mol Biol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3390\/v17081044","article-title":"Subtype-specific HIV-1 protease and the role of hinge and flap dynamics in drug resistance: a subtype C narrative","volume":"17","author":"Sherry","year":"2025","journal-title":"Viruses"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2025.08.004","article-title":"Predictive and therapeutic applications of protein language models","volume":"74","author":"Furui","year":"2025","journal-title":"Allergol Int"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115389","article-title":"Design, synthesis, and biological evaluation of novel HIV-1 protease inhibitors containing pyrrolidine-derived P2 ligands to combat drug-resistant variant","volume":"255","author":"Zhou","year":"2023","journal-title":"Eur J Med Chem"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines14020330","article-title":"Next-generation HIV-1 therapeutics in co-endemic settings","volume":"14","author":"Ngo","year":"2026","journal-title":"Biomedicines"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13112629","article-title":"HIV therapy: The latest developments in antiviral drugs-a scoping review","volume":"13","author":"Fanjul","year":"2025","journal-title":"Biomedicines"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiolchem.2025.108573","article-title":"Zinc C293 as a novel scaffold with dual activity against HIV-1 integrase and reverse transcriptase","volume":"119","author":"Sayyed","year":"2025","journal-title":"Comput Biol Chem"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.2c01422","article-title":"The (Re)-evolution of quantitative structure-activity relationship (QSAR) studies propelled by the surge of machine learning methods","volume":"62","author":"Soares","year":"2022","journal-title":"J Chem Inf Model"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1080\/20565623.2025.2483631","article-title":"Tracking protein kinase targeting advances: integrating QSAR into machine learning for kinase-targeted drug discovery","volume":"11","author":"Shahin","year":"2025","journal-title":"Future Sci OA"},{"key":"B117","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13321-025-01013-4","article-title":"Generalizable, fast, and accurate DeepQSPR with fastprop","volume":"17","author":"Burns","year":"2025","journal-title":"J Cheminform"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26146807","article-title":"Digital alchemy: The rise of machine and deep learning in small-molecule drug discovery","volume":"26","author":"Manan","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.5c04997","article-title":"A systematic review of drug-related interactions\u2500utilizing deep learning and LLMs for prediction and mitigation","volume":"10","author":"Behrooznia","year":"2025","journal-title":"ACS Omega"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1873962\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:34:22Z","timestamp":1789464862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1873962\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":119,"alternative-id":["10.3389\/fimmu.2026.1873962"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1873962","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1873962"}}